Neurostimulation Market Set To Grow To Over $19bn By 2027

13 August 2018
Pharma

Visiongain has launched a new pharma report Forecasts By Product (Spinal Cord Stimulators, Deep Brain Stimulators, Vagus Nerve Stimulators, Sacral Nerve Stimulators, Cortical Stimulators and Others), By Application (Epilepsy, Pain Management, Hearing Loss, Incontinence, Gastroparesis, Parkinson’s Disease and Others) and Geography

The prevalence rates of the spectrum of neurological disorders have been increased significantly in many countries across the globe. According to the Federal Interagency Forum on Aging-Related Statistics, around 35.8% of those 85 or older have moderate or severe memory impairment. Persons 85 years and older are the fastest growing segment of the population. In the U.S., around 1.2 million people aged 18 years and older who are diagnosed annually with adult onset brain disease/disorders.

Neurostimulation is an advanced treatment which helps to reduce certain types of chronic pain or manage neurological conditions. Neurostimulation devices are surgically implanted in the body of the patient and function through thin wires or leads which help them find relief from chronic pain or other neurological conditions.

The lead Visiongain report analyst for this report commented “The risk of chronic and infectious diseases increases with age. Among the geriatric population, the chronic diseases prevalence rate is 64/1,000 persons. The trend of the current rapid rise in elderly population is observed in many regions globally, which is expected to increase the number of patients suffering from chronic diseases such as epilepsy, consequently increasing the demand for various medical devices required for various procedures.”

Thus, with increasing incidence of neurological diseases, the demand for neurostimulation devices is expected to increase significantly in the next few years.

Leading companies who are active in the Neurostimulation market and are featured in the report include Advanced Bionics, Boston Scientific Corporation, Cochlear ltd, Cyberonics, Medtronic Neuronetics Inc, Nervo Corp., Cogentic Medical Inc, St Jude Medical and NDI Medical.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“The worldwide industry for silicone additives is likely to experience important development”, says Visiongain

It is anticipated that the benefits of silicone additives such as elevated drop, marine strength, and leveling & humidity regulate will boost their use in cosmetics, coatings, and paint applications.

16 October 2019

Read

“Global nephrology and urology devices market is anticipated to surpass USD 39 Bn by 2030”, says Visiongain

Nephrology is a field of medicine that is concerned with studying kidney function, treating kidney issues, and therapy for renal substitute.

16 October 2019

Read

“The global Nasal Drug Delivery Technology market is anticipated to surpass USD 80 Billion by 2030”, says Visiongain

Asia Pacific region is anticipated to experience the highest growth in terms of CAGR over the forecast period owing to the availability of effective treatment methods, high unmet clinical needs, rising disposable income levels, and increasing awareness about these products.

16 October 2019

Read

“The global Myeloproliferative Disorders Drugs market is anticipated to surpass USD 11 Bn by 2030”, says Visiongain

The emergence of a new therapy for myeloproliferative disorders and the accessibility of new drugs is anticipated to drive the market drugs for myeloproliferative disorders.

16 October 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever